6 news items
Where Maravai LifeSciences Stands With Analysts
MRVI
9 May 24
, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
MRVI
18 Apr 24
to ensuring the safety and efficacy of this new class of medicines for patients."
Company and site leadership
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
MRVI
10 Apr 24
of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene
Market Momentum: NASDAQ SmallCaps Sparking Waves in March 2024: CELZ, DYAI, GROM, VTAK, BREA
BREA
CELZ
DIS
8 Mar 24
web filtering technology, family-friendly content, and social media safety solutions designed for children. On March 7, the company unveiled
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
MRVI
22 Feb 24
Safety
8hgukzrjlzykb7 1043b6z6p1l1vsa8vaawfonmd
DYAI
MRVI
13 Feb 24
and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. For more information on Cygnus
- Prev
- 1
- Next